concurrent treatment with tamoxifen and cyp2d6 inibitors: clinical significance of drug interactions

Clicks: 211
ID: 175799
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #101 of 231 articles by views in planta medica

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 231 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
Tamoxifen is used in the treatment of women with endocrine responsive breast cancer. It is a prodrug, which is metabolized by liver cytochrome P450 system (CYP) into metabolites with a potent anti-estrogenic activity; CYP2D6 is one of the most important enzymes involved in this metabolic pathway. Low or absent activity of CYP2D6, which can be inherited and/or can occur due to the use of CYP2D6 inhibitors, may impair outcome in women with tamoxifentreated breast cancer. Antidepressants, which can also inhibit CYP2D6, are among the most commonly prescribed drugs in women with breast cancer. Breast cancer patients receiving tamoxifen should not be co-prescribed antidepressants or any other drugs, which are potent inhibitors of CYP2D6.
Reference Key
eruga2012zdravnikiconcurrent Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Boštjan Šeruga;Brigita Novak Šarotar;Lea Knez;Simona Borštnar;Rado Janša;Marga Kocmur;Tanja Čufer
Journal planta medica
Year 2012
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.